About Chemo calendar
With chemotherapy alone (HR, 0.62; 95% CI, 0.52-0.75; P P Safety InsightsSafety was examined in 1534 patients who received single-agent tislelizumab at the approved dosing regimen, as well as 1319 patients with gastric/GEJ cancer, ESCC, or non–small cell lung cancer who received tislelizumab at the approved dosing regimen plus chemotherapy. The most common grade 3 or 4 toxicities experienced with the agent when given with chemotherapy were neutropenia, thrombocytopenia, anemia, fatigue, hypokalemia, hyponatremia, pneumonia, reduced appetite, rash, lymphopenia, increased alanine and aspartate aminotransferase levels, diarrhea, pneumonitis, and hepatitis.1ReferencesBeiGene receives positive CHMP opinions for TEVIMBRA as a first-line treatment for advanced/metastatic gastric or gastroesophageal junction cancer and esophageal squamous cell carcinoma. News release. BeiGene. October 21, 2024. Accessed October 21, 2024. R-H, Oh D-Y, Kato K, et al. Tislelizumab (tis) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study. Ann Oncol. 2023;34(suppl 4):S1526-S1527. doi:10.1016/j.annonc.2023.10.274Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483-495. doi:10.1016/S1470-2045(23)00108-0
Key features of the Chemo calendar that are enabled through these drivers include:
- 15-Round Chemo Treatment Countdown Calendar for Cancer - Etsy
- MARS 2: Chemo Alone May Be Superior to Surgery Plus Chemo
- Chemo Makeup Guide - Headcovers.com
- A noninvasive treatment for chemo brain
- Easy and Beautiful Chemo Countdown
- Cate Levi: Chemo Caps - amazon.com
- Amazon.ca: Cate Levi: Chemo Caps
AbstractBackgroundThe treatment of locally advanced rectal cancer (LARC) has evolved following recent landmark trials of total neoadjuvant therapy (TNT)—the delivery of preoperative chemotherapy sequenced with radiation.AimTo assess the preferences of colorectal surgery (CRS), radiation oncology (RO) and medical oncology (MO) specialists attending the All-Ireland Colorectal Cancer Conference (AICCC) 2022 regarding the neoadjuvant management of LARC.MethodsA live electronic survey explored the preferred treatment approach and TNT regimen for early-, intermediate-, bad-, and advanced-risk categories of rectal cancer according to the European Society of Medical Oncology (ESMO) guidelines. The survey was preceded by an update from lead investigators of TNT trials (OPRA, PRODIGE-23 and RAPIDO), who then participated in a multidisciplinary panel discussion.ResultsTen CRS, 7 RO and 15 MO (32 of 45 specialists) participated fully in the survey resulting in a response rate of 71%. Ninety-four percent, 76% and 53% of specialists preferred a TNT approach for patients with advanced, bad, and intermediate-risk rectal cancer, respectively. A consolidation TNT regimen of long-course chemoradiotherapy followed by chemotherapy was the most preferred regimen. Upfront surgery was preferred by 77% for early-risk disease.ConclusionThis survey illustrated the general acceptance of TNT by rectal cancer specialists attending the AICCC as a valuable treatment strategy for higher-risk category LARC. Whilst the treatment of LARC changes, it remains best practice to individualize care, incorporating the selective use of TNT as discussed by an MDT and in keeping with the patient’s goals of care. Similar content being viewed by others IntroductionNeoadjuvant (chemo)radiotherapy followed by total mesorectal excision is a well-established standard of care for locally advanced rectal cancer (LARC), contributing to lower rates of local recurrence [1]. Despite this approach, almost a third of patients suffer distant metastatic relapse resulting in death in most cases [1, 2]. The impact of adjuvant chemotherapy in this context is unclear as many trials have suffered from poor accrual, low compliance and an inconsistent survival benefit leading to variable implementation across institutions [3,4,5,6].The principal tenet of total neoadjuvant therapy (TNT) is that chemotherapy compliance improves when administered preoperatively in sequence with (chemo)radiotherapy, leading to a reduction in distant metastases. Additional benefits include the potential
